Acquired amegakaryocytic thrombocytopenic purpura: a review of therapeutic options
Department
Internal Medicine
Document Type
Article
Publication Title
Hematology/Oncology and Stem Cell Therapy
Abstract
Acquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare bone marrow disorder characterized by either a marked decrease or a complete absence of megakaryocytes with preservation of all other cell lines. More than 60 cases of AATP have been reported in literature thus far. Due to the rarity of this disease, no standard treatment guidelines have been established and therapy is based on a handful of case studies and expert opinion. Herein, we provide a comprehensive review on currently utilized therapeutic options for AATP.
First Page
291
Last Page
302
DOI
10.56875/2589-0646.1063
Volume
16
Issue
3
Publication Date
4-2023
PubMed ID
37023223
Recommended Citation
Hussain, S. A., Zafar, A., Faisal, H., & Ud Din, M. A. (2023). Acquired amegakaryocytic thrombocytopenic purpura: a review of therapeutic options. Hematology/Oncology and Stem Cell Therapy, 16 (3), 291-302. https://doi.org/10.56875/2589-0646.1063